Souney P F, Stoukides C A
Brigham and Women's Hospital, Boston, MA 02115.
DICP. 1989 Oct;23(10 Suppl):S29-35. doi: 10.1177/1060028089023s1005.
Since the introduction of cimetidine in 1977, hospital expenditures for the histamine2-receptor antagonists have steadily increased, making them one of the most costly classes of therapeutic agents. As a result of cost considerations, we reviewed the available antiulcer agents in our hospital and evaluated the potential for therapeutic interchange within this group of agents. We found that by using famotidine as the principal agent in our hospital, drug cost savings of approximately $65,000 were realized. Additionally, avoiding the administration of approximately 13,000 parenteral doses with the selection of famotidine resulted in further reduction of drug administration costs. We conclude that the histamine2-receptor antagonists represent a cost-effective target for pharmacy cost-containment programs, without affecting patient therapeutic outcomes.
自1977年西咪替丁问世以来，医院用于组胺2受体拮抗剂的支出稳步增加，使其成为最昂贵的治疗药物类别之一。出于成本考虑，我们审查了我院现有的抗溃疡药物，并评估了该类药物治疗性互换的可能性。我们发现，通过在我院将法莫替丁作为主要药物使用，实现了约65,000美元的药品成本节约。此外，选择法莫替丁避免了约13,000剂肠胃外给药，进一步降低了药物给药成本。我们得出结论，组胺2受体拮抗剂是药房成本控制计划中具有成本效益的目标，且不影响患者的治疗效果。
